Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1965 Apr;44(4):518–534. doi: 10.1172/JCI105165

The Initiation and Enhancement of Human Red Cell Lysis by Activators of the First Component of Complement and by First Component Esterase; Studies Using Normal Red Cells and Red Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria*

Stanley Yachnin 1,†, Janet M Ruthenberg 1
PMCID: PMC292519  PMID: 14278168

Full text

PDF
518

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABRAHAM J., HINZ C. F., Jr, PILLEMER L. Requirement for properdin in hemolysis of human erythrocytes treated with tannic acid. Proc Soc Exp Biol Med. 1957 Jan;94(1):230–232. doi: 10.3181/00379727-94-22908. [DOI] [PubMed] [Google Scholar]
  2. AUSTEN K. F., COHN Z. A. Contribution of serum and cellular factors in host defense reactions. I. Serumfactors in host resistanc. N Engl J Med. 1963 Apr 25;268:933–contd. doi: 10.1056/NEJM196304252681707. [DOI] [PubMed] [Google Scholar]
  3. BECKER E. L. Concerning the mechanism of complement action. V. The early steps in immune hemolysis. J Immunol. 1960 Mar;84:299–308. [PubMed] [Google Scholar]
  4. BOYDEN S. V., ANDERSEN M. E. Agglutination of normal erythrocytes in mixtures of antibody and antigen, haemolysis in the presence of complement. Br J Exp Pathol. 1955 Apr;36(2):162–170. [PMC free article] [PubMed] [Google Scholar]
  5. CHRISTIAN C. L., HATFIELD W. B., CHASE P. H. Systemic lupus erythematosus. Cryoprecipitation of sera. J Clin Invest. 1963 Jun;42:823–829. doi: 10.1172/JCI104774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. CHRISTIAN C. L. Studies of aggregated gamma-globulin. I. Sedimentation, electrophoretic and anticomplementary properties. J Immunol. 1960 Jan;84:112–116. [PubMed] [Google Scholar]
  7. CROSBY W. H. Paroxysmal nocturnal hemoglobinuria: relation of the clinical manifestations to underlying pathogenic mechanisms. Blood. 1953 Sep;8(9):769–812. [PubMed] [Google Scholar]
  8. DACIE J. V. The presence of cold haemolysins in sera containing cold haemagglutinins. J Pathol Bacteriol. 1950 Apr;62(2):241–257. doi: 10.1002/path.1700620212. [DOI] [PubMed] [Google Scholar]
  9. DAMESHEK W., FUDENBERG H. Paroxysmal nocturnal hemoglobinuria. AMA Arch Intern Med. 1957 Feb;99(2):202–208. doi: 10.1001/archinte.1957.00260020038006. [DOI] [PubMed] [Google Scholar]
  10. FREEDMAN P., MARKOWITZ A. S. Gamma globulin and complement in the diseased kidney. J Clin Invest. 1962 Feb;41:328–334. doi: 10.1172/JCI104486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. HAINES A. L., LEPOW I. H. STUDIES ON HUMAN C'1-ESTERASE. I. PURIFICATION AND ENZYMATIC PROPERTIES. J Immunol. 1964 Mar;92:456–467. [PubMed] [Google Scholar]
  12. HAINES A. L., LEPOW I. H. STUDIES ON HUMAN C'1-ESTERASE. II. FUNCTION OF PURIFIED C'1-ESTERASE IN THE HUMAN COMPLEMENT SYSTEM. J Immunol. 1964 Mar;92:468–478. [PubMed] [Google Scholar]
  13. HEWITT B. R. Spectrophotometric determination of protein in alkaline solution. Nature. 1958 Jul 26;182(4630):246–246. [PubMed] [Google Scholar]
  14. HINZ C. F., Jr, HURLEY T. H., WEISMAN R., Jr Paroxysmal nocturnal hemoglobinuria; relationship of in vitro and in vivo hemolysis to clinical severity. J Lab Clin Med. 1956 Oct;48(4):495–510. [PubMed] [Google Scholar]
  15. HINZ C. F., Jr, JORDAN W. S., Jr, PILLEMER L. The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1956 May;35(5):453–457. doi: 10.1172/JCI103296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. HINZ C. F., Jr, MOLLNER A. M. STUDIES ON IMMUNE HUMAN HEMOLYSIS. III. ROLE OF 11 S COMPONENT IN INITIATING THE DONATH-LANDSTEINER REACTION. J Immunol. 1963 Oct;91:512–517. [PubMed] [Google Scholar]
  17. Ham T. H., Dingle J. H. STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT. J Clin Invest. 1939 Nov;18(6):657–672. doi: 10.1172/JCI101081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. LACHMANN P. J., MULLER-EBERHARD H. J., KUNKEL H. G., PARONETTO F. The localization of in vivo bound complement in tissue section. J Exp Med. 1962 Jan 1;115:63–82. doi: 10.1084/jem.115.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. LEPOW I. H., NAFF G. B., TODD E. W., PENSKY J., HINZ C. F. Chromatographic resolution of the first component of human complement into three activities. J Exp Med. 1963 Jun 1;117:983–1008. doi: 10.1084/jem.117.6.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. LEPOW I. H., PILLEMER L. Studies on the mechanism of inactivation of human complement by plasmin and by antigen-antibody aggregates. II. Demonstration of two distinct reaction stages in complement fixation. J Immunol. 1955 Jul;75(1):63–70. [PubMed] [Google Scholar]
  21. LEPOW I. H., WURZ L., RATNOFF O. D., PILLEMER L. Studies on the mechanism of inactivation of human complement by plasmin and by antigen-antibody aggregates. I. The requirement for a factor resembling C'1 and the role of Ca++. J Immunol. 1954 Sep;73(3):146–158. [PubMed] [Google Scholar]
  22. LEVINE L., OSLER A. G., MAYER M. M. Studies on the role of Ca++ and Mg++ in complement fixation and immune hemolysis. III. The respective roles of Ca++ and Mg++ in immune hemolysis. J Immunol. 1953 Nov;71(5):374–379. [PubMed] [Google Scholar]
  23. LEVY L. R., LEPOW I. H. Assay and properties of serum inhibitor of C'l-esterase. Proc Soc Exp Biol Med. 1959 Aug-Sep;101:608–611. doi: 10.3181/00379727-101-25034. [DOI] [PubMed] [Google Scholar]
  24. LINSCOTT W. D., NISHIOKA K. COMPONENTS OF GUINEA PIG COMPLEMENT. II. SEPARATION OF SERUM FRACTIONS ESSENTIAL FOR IMMUNE HEMOLYSIS. J Exp Med. 1963 Nov 1;118:795–815. doi: 10.1084/jem.118.5.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. MARCUS D. M. A study of the mechanism of the anticomplementary activity of gamma-globulin. J Immunol. 1960 Mar;84:273–284. [PubMed] [Google Scholar]
  26. MIDDLEBROOK G. Antigens of tubercle bacillus involved in hemagglutination and hemolysis reactions. Bull N Y Acad Med. 1952 Jul;28(7):474–475. [PMC free article] [PubMed] [Google Scholar]
  27. MUELLER-EBERHARD H. J., BIRO C. E. ISOLATION AND DESCRIPTION OF THE FOURTH COMPONENT OF HUMAN COMPLEMENT. J Exp Med. 1963 Sep 1;118:447–466. doi: 10.1084/jem.118.3.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. NETER E., BERTRAM L. F., ZAK D. A., MURDOCK M. R., ARBESMAN C. E. Studies on hemagglutination and hemolysis by escherichia coli antisera. J Exp Med. 1952 Jul;96(1):1–15. doi: 10.1084/jem.96.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. NETER E., WESTPHAL O., LUDERITZ O. Effects of lecithin, cholesterol, and serum on erythrocyte modification and antibody neutralization by enterobacterial lipopolysaccharides. Proc Soc Exp Biol Med. 1955 Mar;88(3):339–341. doi: 10.3181/00379727-88-21582. [DOI] [PubMed] [Google Scholar]
  30. OZER F. L., CHAPLIN H., Jr AGGLUTINATION OF STORED ERYTHROCYTES BY A HUMAN SERUM. CHARACTERIZATION OF THE SERUM FACTOR AND ERYTHROCYTE CHANGES. J Clin Invest. 1963 Nov;42:1735–1752. doi: 10.1172/JCI104859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. PENSKY J., LEVY L. R., LEPOW I. H. Partial purification of a serum inhibitor of C'1-esterase. J Biol Chem. 1961 Jun;236:1674–1679. [PubMed] [Google Scholar]
  32. PILLEMER L., BLUM L., LEPOW I. H., ROSS O. A., TODD E. W., WARDLAW A. C. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954 Aug 20;120(3112):279–285. doi: 10.1126/science.120.3112.279. [DOI] [PubMed] [Google Scholar]
  33. RATNOFF O. D., LEPOW I. H. COMPLEMENT AS A MEDIATOR OF INFLAMMATION. ENHANCEMENT OF VASCULAR PERMEABILITY BY PURIFIED HUMAN C'1 ESTERASE. J Exp Med. 1963 Nov 1;118:681–698. doi: 10.1084/jem.118.5.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. TAYLOR C. E., WALTON K. W. The molecular characteristics determining the anticomplementary activity of dextran sulphates. Br J Exp Pathol. 1957 Jun;38(3):248–255. [PMC free article] [PubMed] [Google Scholar]
  35. YACHNIN S. BIOLOGIC PROPERTIES OF POLYNUCLEOTIDES. I. THE ANTICOMPLEMENTARY ACTIVITY OF POLYNUCLEOTIDES. J Clin Invest. 1963 Dec;42:1947–1955. doi: 10.1172/JCI104881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. YACHNIN S., GARDNER F. H. Measurement of human erythrocyte neuraminic acid: relationship to haemolysis and red blood cell virus interaction. Br J Haematol. 1961 Oct;7:464–475. doi: 10.1111/j.1365-2141.1961.tb00356.x. [DOI] [PubMed] [Google Scholar]
  37. YACHNIN S., ROSENBLUM D. BIOLOGIC PROPERTIES OF POLYNUCLEOTIDES. IV. STUDIES ON THE MECHANISM OF COMPLEMENT INHIBITION BY POLYINOSINIC ACID TOGETHER WITH OBSERVATIONS ON THE IN VIVO EFFECT OF POLYINOSINIC ACID ON COMPLEMENT ACTIVITY. J Clin Invest. 1964 Jun;43:1175–1184. doi: 10.1172/JCI105001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. YACHNIN S., ROSENBLUM D., CHATMAN D. BIOLOGIC PROPERTIES OF POLYNUCLEOTIDES. V. STUDIES ON THE INHIBITION OF THE FIRST COMPONENT OF COMPLEMENT BY POLYINOSINIC ACID: THE INTERACTION WITH C'1Q. J Immunol. 1964 Oct;93:540–548. [PubMed] [Google Scholar]
  39. YACHNIN S., ROSENBLUM D., CHATMAN D. BIOLOGIC PROPERTIES OF POLYNUCLEOTIDES. VI. FURTHER STUDIES ON THE MECHANISM OF COMPLEMENT INHIBITION BY POLYINOSINIC ACID: THE INACTIVATION OF THE FOURTH COMPONENT OF COMPLEMENT. J Immunol. 1964 Oct;93:549–557. [PubMed] [Google Scholar]
  40. YACHNIN S., RUTHENBERG J. M. PH OPTIMA IN IMMUNE HEMOLYSIS: A COMPARISON BETWEEN GUINEA PIG AND HUMAN COMPLEMENT. J Clin Invest. 1965 Jan;44:149–158. doi: 10.1172/JCI105121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. YACHNIN S., RUTHENBERG J. ROLE OF CALCIUM IN COMPLEMENT DEPENDENT HEMOLYSIS. Proc Soc Exp Biol Med. 1964 Oct;117:179–181. doi: 10.3181/00379727-117-29529. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES